Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma

Table 2 Risk factors for post-liver transplant direct-acting antiviral therapy response (Logistic regression analysis)

Variable	Number of DAA therapy responses/failures (n = 100/6)	Univariate OR (95%CI)	P value	Multivariate OR (95%CI)	P value
Age > 60 yr	60/4	1.3 (0.2-15.4)	0.8
Male	70/5	2.1 (0.2-104.7)	0.9
Baseline BMI (≥ 25 kg/m2)	76/5	1.6 (0.2-77.7)	0.9
Alcohol drinking	39/4	3.1 (0.4-35.7)	0.4
Cigarette smoking	64/5	2.8 (0.3-136.6)	0.6
Diabetes Mellitus	70/3	0.4 (0.1-3.4)	0.5
CKD	42/1	0.30 (0.01-2.60)	0.4
Cirrhosis	9/0	-
Pre-LT relapse to DAA	25/4	5.9 (0.8-68.7)	0.09
Anti-HBc-positive allograft	9/2	4.9 (0.4-40.4)	0.2
HCV-positive allograft	2/2	22.0 (1.3-381.3)	0.02	3.2 (0.1-856.8)	0.8
HCV genotype 3a	15/4	10.9 (1.4-130.9)	0.03	1.40 (0.02-89.10)	0.9
Presence of HCC before LT	63/5	2.9 (0.3-142.6)	0.6
Rejection during/after DAA therapy	5/0	-	-
ALT level at treatment week 4 (> 35 IU/L)	16/4	1.02 (1.00-1.05)	0.001	1.04 (1.00-1.10)	0.04
Quantitative HCV PCR at treatment week 4 (> 15 IU/mL)	8/3	10.9 (1.3-96.4)	0.01	3.6 (0.1-172.3)	0.5

HCC: Hepatocellular carcinoma; BMI: Body mass index; CKD: Chronic kidney disease; DAA: Direct-acting antiviral; HCV: Hepatitis C virus; OR: Odds ratio; CI: Confidence interval; ALT: Alanine aminotransferase; LT: Liver transplant; HBc: Hepatitis B core; PCR: Polymerase chain reaction.